Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia

According to World Health Organization (WHO)-defined criteria, patients presenting clinically as essential thrombocythemia (ET) may show early primary myelofibrosis (PMF) with accompanying thrombocythemia [1]. Previous clinicopathological studies revealed that laboratory parameters like gender-matched hemoglobin (Hb), white blood cell (WBC) count, and particularly lactate dehydrogenase (LDH) values are significantly different in PMF [2]. By strictly applying the WHO criteria, our investigation was aimed to study sensitivity and specificity of these features in an exploratory cohort of 536 patients and to validate the results on an independently recruited series of 321 strictly corresponding patients. The discriminatory power of these parameters (Hb, WBC, and LDH) was tested by plotting their receiver operating characteristic curves. The best performance was found for LDH (areas under the curve, AUC 5 0.7059). WBC and Hb had superimposable curves, with AUC of 0.6279 and 0.6257, respectively. A diagnostic algorithm was generated by applying these parameters in a stepwise fashion. Nearly half of the patients could be correctly allocated to WHO-defined ET or early PMF in both cohorts investigated. It is important to note that this result does not substitute bone marrow morphology with hematological parameters, however, in clinical practice may alert physicians to get more suspicious of early PMF in a patient presumably presenting with ET.

[1]  C. Smith Diagnostic tests (1) – sensitivity and specificity , 2012, Phlebology.

[2]  M. Di Nisio,et al.  Diagnosis and treatment of disseminated intravascular coagulation: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). , 2012, Thrombosis research.

[3]  Scott T. Miller,et al.  Stroke with transfusions changing to hydroxyurea (SWiTCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload , 2011, Pediatric blood & cancer.

[4]  J. Freedman,et al.  The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies. , 2011, The Journal of clinical investigation.

[5]  A. Kiani,et al.  Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse , 2011, Haematologica.

[6]  T. Barbui,et al.  Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Ogawa,et al.  Novel CUX1 missense mutation in association with 7q− at leukemic transformation of MPN , 2011, American journal of hematology.

[8]  P. Fu,et al.  Spontaneous autologous graft-versus-host disease in plasma cell myeloma autograft recipients: flow cytometric analysis of hematopoietic progenitor cell grafts. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  H. Gisslinger,et al.  Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. , 2011, Blood.

[10]  L. Farrer,et al.  A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. , 2011, Blood.

[11]  A. Tefferi,et al.  Isolated del(5q) in myeloid malignancies: Clinicopathologic and molecular features in 143 consecutive patients , 2011, American journal of hematology.

[12]  L. Manco,et al.  Chronic hemolytic anemia is associated with a new glucose-6-phosphate dehydrogenase in-frame deletion in an older woman. , 2011, Blood cells, molecules & diseases.

[13]  A. Tefferi,et al.  Autosomal monosomies among 24,262 consecutive cytogenetic studies: Prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities , 2011, American journal of hematology.

[14]  A. Tefferi,et al.  Circulating levels of MCP‐1, sIL‐2R, IL‐15, and IL‐8 predict anemia response to pomalidomide therapy in myelofibrosis , 2011, American journal of hematology.

[15]  Steve Evans,et al.  The DEDUCE Guided Query tool: Providing simplified access to clinical data for research and quality improvement , 2011, J. Biomed. Informatics.

[16]  I. Buccimazza Implementing Sentinel Lymph Node Biopsy Programs in Developing Countries: Challenges and Opportunities , 2011, World Journal of Surgery.

[17]  P. Hokland,et al.  Towards individualized follow-up in adult acute myeloid leukemia in remission. , 2011, Blood.

[18]  M. Cazzola,et al.  p53 lesions in leukemic transformation. , 2011, The New England journal of medicine.

[19]  M. Boeckh,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients. , 2011, Hematology/oncology clinics of North America.

[20]  W. Stock,et al.  Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML , 2010, Bone Marrow Transplantation.

[21]  V. Pinto,et al.  Manual erythroexchange for chronic transfusion therapy in patients with sickle cell syndromes unresponsive to hydroxyurea: A long‐term follow‐up , 2010, American journal of hematology.

[22]  Joel N Hirschhorn,et al.  Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation , 2010, Nature Genetics.

[23]  W. Arcese,et al.  Standard‐ versus high‐dose lenograstim in adults with hematologic malignancies for peripheral blood progenitor cell mobilization , 2010, Transfusion.

[24]  B. Tutschek,et al.  Fetal alloimmune thrombocytopenia and maternal intravenous immunoglobulin infusion , 2010, Haematologica.

[25]  J. Mayer,et al.  Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient‐specific NPM1 mutations , 2010, American journal of hematology.

[26]  A. Tefferi,et al.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.

[27]  J. Mandrekar Receiver operating characteristic curve in diagnostic test assessment. , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[28]  A. Tefferi,et al.  LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations , 2010, Leukemia.

[29]  S. Thein,et al.  Binding patterns of BCL11A in the globin and GATA1 loci and characterization of the BCL11A fetal hemoglobin locus. , 2010, Blood cells, molecules & diseases.

[30]  M. Franchini,et al.  Disseminated intravascular coagulation in hematologic malignancies. , 2010, Seminars in thrombosis and hemostasis.

[31]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[32]  A. Tefferi,et al.  IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms , 2010, Leukemia.

[33]  M. Cazzola,et al.  Deletions of the transcription factor Ikaros in myeloproliferative neoplasms , 2010, Leukemia.

[34]  R. Hills,et al.  European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Stephen W. Hartley,et al.  Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. , 2010, Blood.

[36]  D. Steensma,et al.  Host immunity affects survival in myelodysplastic syndromes: Independent prognostic value of the absolute lymphocyte count , 2010, American journal of hematology.

[37]  J. Freedman,et al.  A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. , 2010, Blood.

[38]  J. Gabrilove,et al.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. Kasman,et al.  A systematic approach to virus–virus interactions , 2010, Virus Research.

[40]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[41]  R. Adams,et al.  Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. , 2009, Blood.

[42]  H. Wajcman,et al.  A rare G6PD variant (c.383T>G; p.128Leu>Arg) with a molecular pathophysiological mechanism similar to that of G6PD A- (68Val>Met, 126Asn>Asp). , 2009, Blood cells, molecules & diseases.

[43]  E. Jaffe,et al.  Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report , 2009, Haematologica.

[44]  Serena Sanna,et al.  Amelioration of Sardinian beta0 thalassemia by genetic modifiers. , 2009, Blood.

[45]  F. Passamonti,et al.  Transfusion‐dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis—prognostic relevance is independent of IPSS or karyotype , 2009, American journal of hematology.

[46]  Chad Garner,et al.  Control of fetal hemoglobin: new insights emerging from genomics and clinical implications. , 2009, Human molecular genetics.

[47]  O. Abdel-Wahab,et al.  Cytogenetic correlates of TET2 mutations in 199 patients with myeloproliferative neoplasms , 2009, American journal of hematology.

[48]  Katherine G. Evans,et al.  Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma. , 2009, Archives of dermatology.

[49]  M. Lathrop,et al.  The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. , 2009, Blood.

[50]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[51]  A. Bayram,et al.  Prevalence of human cytomegalovirus co-infection in patients with chronic viral hepatitis B and C: a comparison of clinical and histological aspects. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[52]  Martin Klabusay,et al.  Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression. , 2009, Experimental hematology.

[53]  D. Steensma,et al.  Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does not , 2009, American journal of hematology.

[54]  J. Thachil,et al.  Guidelines for the diagnosis and management of disseminated intravascular coagulation , 2009, British journal of haematology.

[55]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[56]  M. Levi Disseminated intravascular coagulation in cancer patients. , 2009, Best practice & research. Clinical haematology.

[57]  O. Frankfurt,et al.  The coagulopathy of acute promyelocytic leukaemia revisited. , 2009, Best practice & research. Clinical haematology.

[58]  F. Passamonti,et al.  Survival in young patients with intermediate‐/high‐risk myelofibrosis: Estimates derived from databases for non transplant patients , 2009, American journal of hematology.

[59]  M. Farrall,et al.  Genetic Variation on Chromosome 6 Influences F Cell Levels in Healthy Individuals of African Descent and HbF Levels in Sickle Cell Patients , 2009, PloS one.

[60]  J. Wood Cardiac iron across different transfusion-dependent diseases. , 2008, Blood reviews.

[61]  H. Ni,et al.  Fc-independent phagocytosis: implications for intravenous IgG therapy in immune thrombocytopenia. , 2008, Cardiovascular & hematological disorders drug targets.

[62]  P. Sebastiani,et al.  BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. , 2008, Blood cells, molecules & diseases.

[63]  E. Vichinsky,et al.  Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions , 2008, Transfusion.

[64]  M. Hou,et al.  Increased cytotoxic T-lymphocyte-mediated cytotoxicity predominant in patients with idiopathic thrombocytopenic purpura without platelet autoantibodies , 2008, Haematologica.

[65]  J. Hirschhorn,et al.  DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease , 2008, Proceedings of the National Academy of Sciences.

[66]  H. Einsele,et al.  Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT , 2008, Bone Marrow Transplantation.

[67]  A. Bergen,et al.  Multiplex ligation-dependent probe amplification (MLPA) enhances the molecular diagnosis of aniridia and related disorders , 2008, Molecular vision.

[68]  A. Boscolo,et al.  Protein C concentrate to restore physiological values in adult septic patients , 2008, Intensive Care Medicine.

[69]  Jin-Hwang Liu,et al.  Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation , 2008, Annals of Hematology.

[70]  Po-min Chen,et al.  Virus reactivation in high-risk non-Hodgkin’s lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation , 2008, International journal of hematology.

[71]  S. Baker,et al.  Liver biopsy results in patients with sickle cell disease on chronic transfusions: Poor correlation with ferritin levels , 2008, Pediatric blood & cancer.

[72]  E. Olson,et al.  Deacetylase inhibition promotes the generation and function of regulatory T cells , 2007, Nature Medicine.

[73]  K. Ataga,et al.  β‐Thalassaemia and sickle cell anaemia as paradigms of hypercoagulability , 2007, British journal of haematology.

[74]  Simon Heath,et al.  A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15 , 2007, Nature Genetics.

[75]  L. Montaner,et al.  Synthetic imidazoquinolines potently and broadly activate the cellular immune response of patients with cutaneous T-cell lymphoma: synergy with interferon-gamma enhances production of interleukin-12. , 2007, Clinical lymphoma & myeloma.

[76]  C. Bloomfield,et al.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. , 2007, Blood.

[77]  P. Marks,et al.  Histone deacetylase inhibitors: molecular mechanisms of action , 2007, Oncogene.

[78]  W. Drew,et al.  Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients , 2007, Current opinion in infectious diseases.

[79]  Drew Wl Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. , 2007 .

[80]  T. Spector,et al.  Intergenic variants of HBS1L-MYB are responsible for a major quantitative trait locus on chromosome 6q23 influencing fetal hemoglobin levels in adults , 2007, Proceedings of the National Academy of Sciences.

[81]  K. Kalies,et al.  Significant high expression of CD23 in follicular lymphoma of the inguinal region , 2007, Histopathology.

[82]  D. Hommes,et al.  Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression. , 2007, Trends in molecular medicine.

[83]  F. Mandelli,et al.  Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. , 2007, Blood.

[84]  Xiang Y. Han Epidemiologic Analysis of Reactivated Cytomegalovirus Antigenemia in Patients with Cancer , 2007, Journal of Clinical Microbiology.

[85]  J. Esteve,et al.  Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention , 2007, Leukemia.

[86]  R. Go,et al.  The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. , 2006, Haematologica.

[87]  E. Vichinsky,et al.  Increased prevalence of iron‐overload associated endocrinopathy in thalassaemia versus sickle‐cell disease , 2006, British journal of haematology.

[88]  D. Horn,et al.  Bloodstream infections in hospitalized adults with sickle cell disease: A retrospective analysis , 2006, American journal of hematology.

[89]  Dan M. Kluger,et al.  The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. , 2006, Mayo Clinic proceedings.

[90]  J. Freedman,et al.  Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. , 2006, Blood.

[91]  S. Opal,et al.  Coagulation abnormalities in critically ill patients , 2006, Critical care.

[92]  H. Wajcman,et al.  Pyruvate kinase deficiency in France: a 3‐year study reveals 27 new mutations , 2006, British journal of haematology.

[93]  K. Laczika,et al.  Treatment of adult patients with sepsis‐induced coagulopathy and purpura fulminans using a plasma‐derived protein C concentrate (Ceprotin®) , 2006, Vox sanguinis.

[94]  G. Fantuzzi,et al.  Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice1 , 2006, The Journal of Immunology.

[95]  M. Levine,et al.  Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  D. Hockenbery,et al.  Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. , 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[97]  Alessia Moro,et al.  Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoieticbone marrow histology , 2006, Leukemia & lymphoma.

[98]  A. Rosen,et al.  Apoptosis and autoimmunity. , 2005, Current opinion in immunology.

[99]  M. Duvic,et al.  Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. , 2005, The Journal of investigative dermatology.

[100]  M. Fumagalli,et al.  Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program , 2005, Transplant infectious disease : an official journal of the Transplantation Society.

[101]  A. Raj,et al.  Cathlink® 20: A subcutaneous implanted central venous access device used in children with sickle cell disease on long‐term erythrocytapheresis—a report of low complication rates , 2005, Pediatric blood & cancer.

[102]  F. Bennardello,et al.  Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. , 2005, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[103]  S Parodi,et al.  Central venous catheter-related complications in children with oncological/hematological diseases: an observational study of 418 devices. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[104]  M. Levi,et al.  Pathogenesis and treatment of DIC. , 2005, Thrombosis research.

[105]  J. Bussel,et al.  Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies , 2004, American journal of hematology.

[106]  D. Nelson,et al.  Severe protein C deficiency predicts early death in severe sepsis , 2004, Critical care medicine.

[107]  C. Dinarello,et al.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[108]  H. Kantarjian,et al.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. , 2003, Blood.

[109]  G. Papanicolaou,et al.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[110]  B. Olsson,et al.  T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura , 2003, Nature Medicine.

[111]  Shirley A. Williams,et al.  Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. , 2003, Blood.

[112]  P. Mulder,et al.  Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. , 2003, Critical care medicine.

[113]  J. Freedman,et al.  Platelets in hemostasis and thrombosis: role of integrins and their ligands. , 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[114]  J. Thiele,et al.  Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients , 2003, Annals of Hematology.

[115]  G. Gilkeson,et al.  Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. , 2003, The Journal of clinical investigation.

[116]  G. Pamuk,et al.  Overview of 321 patients with idiopathic thrombocytopenic purpura , 2002, Annals of Hematology.

[117]  P. Griffiths,et al.  Definitions of cytomegalovirus infection and disease in transplant recipients. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[118]  L. Medeiros,et al.  Discrepancies in the immunophenotype of lymphoma cells in samples obtained simultaneously from different anatomic sites. , 2002, American journal of clinical pathology.

[119]  G. Trinchieri,et al.  Reciprocal Activating Interaction between Natural Killer Cells and Dendritic Cells , 2002, The Journal of experimental medicine.

[120]  C. Skibola,et al.  Central venous catheter complications in sickle cell disease , 2002, American journal of hematology.

[121]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[122]  J. Dhainaut,et al.  Activated protein C versus protein C in severe sepsis , 2001, Critical care medicine.

[123]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[124]  S. O’Brien,et al.  Hepatitis C virus load is associated with human immunodeficiency virus type 1 disease progression in hemophiliacs. , 2001, The Journal of infectious diseases.

[125]  G. Tricot,et al.  Cytomegalovirus infection and non‐neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphoma , 2001, British journal of haematology.

[126]  B. Nieswandt,et al.  Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. , 2000, Blood.

[127]  C. Fisher,et al.  Protein C levels as a prognostic indicator of outcome in sepsis and related diseases , 2000, Critical care medicine.

[128]  R. Mcmillan Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura. , 2000, Seminars in hematology.

[129]  G. McDonald,et al.  Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. , 2000, The American journal of surgical pathology.

[130]  P. Harmatz,et al.  Severity of Iron Overload in Patients with Sickle Cell Disease Receiving Chronic Red Blood Cell Transfusion Therapy , 2000, Blood.

[131]  M. Cappellini,et al.  Chronic non-spherocytic haemolytic disorders associated with glucose-6-phosphate dehydrogenase variants. , 2000, Bailliere's best practice & research. Clinical haematology.

[132]  S. Au,et al.  Human glucose-6-phosphate dehydrogenase: the crystal structure reveals a structural NADP(+) molecule and provides insights into enzyme deficiency. , 2000, Structure.

[133]  B. Nieswandt,et al.  Structural and functional characterization of the mouse von Willebrand factor receptor GPIb-IX with novel monoclonal antibodies. , 2000, Blood.

[134]  Y. Lian,et al.  [Preliminary study on relationship between different viral pathogenesis and disease prognosis in patients with severe viral hepatitis]. , 1999, Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology.

[135]  J. Clive,et al.  Cytomegalovirus viremia, viruria and disease after autologous peripheral blood stem cell transplantation: no need for surveillance , 1999, Bone Marrow Transplantation.

[136]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[137]  L. Luzzatto,et al.  Solution of the structure of tetrameric human glucose 6-phosphate dehydrogenase by molecular replacement. , 1999, Acta crystallographica. Section D, Biological crystallography.

[138]  M. Ertem,et al.  Platelet autoantibodies in immune thrombocytopenic purpura. , 1998, Transfusion science.

[139]  T. Howard,et al.  Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients , 1998, American journal of hematology.

[140]  D. Hockenbery,et al.  Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. , 1998, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[141]  F. Chisari,et al.  Inhibition of Hepatitis B Virus Replication during Adenovirus and Cytomegalovirus Infections in Transgenic Mice , 1998, Journal of Virology.

[142]  C. Sabin,et al.  Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease , 1998, Bone Marrow Transplantation.

[143]  H. Einsele,et al.  Cytomegalovirus monitoring by polymerase chain reaction of whole blood samples from patients undergoing autologous bone marrow or peripheral blood progenitor cell transplantation. , 1997, The Journal of infectious diseases.

[144]  Jerrold S. Levine,et al.  Apoptosis and autoimmunity , 1997, Current opinion in nephrology and hypertension.

[145]  B. Andersson,et al.  Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[147]  T. Stevens-Ayers,et al.  Cytomegalovirus pp65 antigenemia after autologous marrow and peripheral blood stem cell transplantation. , 1996, The Journal of infectious diseases.

[148]  T. Pearson,et al.  Experience with the Port-A-Cath in sickle cell disease. , 1996, Clinical and laboratory haematology.

[149]  M. Gauderer,et al.  Long‐Term Central Venous Access in Patients with Sickle Cell Disease: Incidence of Thrombotic and Infectious Complications , 1995, Journal of pediatric hematology/oncology.

[150]  M. Boeckh,et al.  Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation. , 1995, The Journal of infectious diseases.

[151]  Scott T. Miller,et al.  Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. , 1995, The Journal of pediatrics.

[152]  A. Hess,et al.  Characterization of the autoreactive T cell repertoire in cyclosporin-induced syngeneic graft-versus-host disease. A highly conserved repertoire mediates autoaggression. , 1995, Journal of immunology.

[153]  G. Trinchieri,et al.  IL-12 reverses cytokine and immune abnormalities in Sezary syndrome. , 1995, Journal of immunology.

[154]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[155]  J. Bland,et al.  Statistics Notes: Diagnostic tests 3: receiver operating characteristic plots , 1994, BMJ.

[156]  C. E. Jones,et al.  Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. , 1994, Blood.

[157]  J. Silber,et al.  Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease. , 1994, Blood.

[158]  Sanfeliu,et al.  [15 years later]. , 1993, Revista de enfermeria.

[159]  C. McLaren,et al.  Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major , 1993, American journal of hematology.

[160]  Richard J. Jones,et al.  Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. , 1992, Blood.

[161]  A. Stansfeld Lymph Node Biopsy Interpretation , 1992 .

[162]  J. Silber,et al.  A modified transfusion program for prevention of stroke in sickle cell disease. , 1992, Blood.

[163]  B. Forget,et al.  δβ Thalassemia and Hereditary Persistence of Fetal Hemoglobin , 1991 .

[164]  A. Piga,et al.  SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.

[165]  S. Piantadosi,et al.  INDUCTION OF GRAFT-VERSUS-HOST DISEASE AFTER AUTOLOGOUS BONE MARROW TRANSPLANTATION , 1989, The Lancet.

[166]  C. Slingluff,et al.  Totally implantable intravenous catheters in the management of sickle cell anemia , 1988, American journal of hematology.

[167]  V. Kiefel,et al.  Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. , 1987, Blood.

[168]  F. Collins,et al.  A point mutation in the Aγ-globin gene promoter in Greek hereditary persistence of fetal haemoglobin , 1985, Nature.

[169]  J. Pizzuto,et al.  Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. , 1984, Blood.

[170]  A. Piga,et al.  Cirrhosis associated with multiple transfusions in thalassaemia. , 1984, Archives of disease in childhood.

[171]  R. Doberneck The diagnostic yield of lymph node biopsy. , 1983, Archives of surgery.

[172]  Hoppe Rt Histologic variation in non-Hodgkin's lymphomas: commentary. , 1981 .

[173]  S. Karpatkin Autoimmune thrombocytopenic purpura. , 1980, The American journal of the medical sciences.

[174]  H. Notopuro,et al.  Glucose-6-phosphate dehydrogenase deficiency. , 1972, Paediatrica Indonesiana.

[175]  H. Watson,et al.  British Committee for Standards in Haematology , 1969 .

[176]  A. Cardona,et al.  Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. , 2011, The Cochrane database of systematic reviews.

[177]  Cardona Af,et al.  Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia (Review) , 2011 .

[178]  A. Kiani,et al.  Successful treatment of molecular relapse in NPM1-positive AML using 5-azacytidine , 2010, Leukemia.

[179]  H. Saba,et al.  Disseminated Intravascular Coagulation (DIC) in cancer. , 2009, Cancer treatment and research.

[180]  C. Kitchens Thrombocytopenia and thrombosis in disseminated intravascular coagulation (DIC). , 2009, Hematology. American Society of Hematology. Education Program.

[181]  D. Gilliland,et al.  Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates , 2009, Leukemia.

[182]  P. Hari,et al.  Severe autologous GVHD after hematopoietic progenitor cell transplantation for multiple myeloma , 2009, Bone Marrow Transplantation.

[183]  T. Cole Glucocorticoid action and the development of selective glucocorticoid receptor ligands. , 2006, Biotechnology annual review.

[184]  Ashley P Ng,et al.  Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation. , 2005, Haematologica.

[185]  Cameron S. Osborne,et al.  The Corfu deltabeta thalassemia deletion disrupts gamma-globin gene silencing and reveals post-transcriptional regulation of HbF expression. , 2005, Blood.

[186]  G. Fantuzzi,et al.  The Histone Deacetylase Inhibitor ITF2357 Reduces Production of Pro-Inflammatory Cytokines In Vitro and Systemic Inflammation In Vivo , 2005, Molecular medicine.

[187]  L. Manco,et al.  Two new glucose-6-phosphate dehydrogenase mutations causing chronic hemolysis. , 2005, Haematologica.

[188]  P. Bierling,et al.  Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. , 2005, Haematologica.

[189]  Ada Maria Florena,et al.  Value of bone marrow biopsy in the diagnosis of essential thrombocythemia. , 2004, Haematologica.

[190]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[191]  M. Levi,et al.  Coagulation: consultative hemostasis. , 2002, Hematology. American Society of Hematology. Education Program.

[192]  C. Thoburn,et al.  Complexity of effector mechanisms in cyclosporine-induced syngeneic graft-versus-host disease. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[193]  S. Heimfeld,et al.  Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. , 1999, Blood.

[194]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[195]  G. Masera,et al.  Growth and sexual maturation in thalassemia major. , 1985, The Journal of pediatrics.

[196]  T. Huisman,et al.  Two Independent Genetic Factors in the j9-Globin Gene Cluster Are Associated With High G7..Levels in the HbF of SS Patients , 1984 .

[197]  R. Hoppe Histologic variation in non-Hodgkin's lymphomas: commentary. , 1981, Cancer treatment reports.

[198]  E. Beutler,et al.  Special modifications of the fluorescent screening method for glucose-6-phosphate dehydrogenase deficiency. , 1968, Blood.